Vaccines have transformed public health, building strong systemic immunity across much of the global population and protecting effectively against many severe infectious diseases. Despite this success, a fundamental mismatch persists between the intramuscular administration route of most vaccines and the mucosal surfaces where many pathogens establish infection.
Systemic immunity acts once a pathogen has already entered the body, limiting its spread and preventing severe illness. What it does not provide is immunity at the body’s primary entry points, so pathogens can still take hold there and spread easily to others. Because of this mucosal immunity gap, vaccines are limited in their ability to stop initial infection and reduce transmission.
Our mission is to close this mucosal immunity gap.
Our Nm-nOMV Platform is designed to close the mucosal immunity gap through the development of scalable multivalent vaccines that induce both systemic and mucosal immunity through three modalities:
Our platform is optimized for safety, scalability, and yield. A set of genetic mutations and manufacturing innovations across fermentation and downstream processing, including a proprietary growth medium and a detergent-free, anti-foam enabled process, delivers high OMV yield with fewer processing steps, enabling scalable manufacturing. These innovations could immediately be applied to both existing and next-generation OMV vaccines. These manufacturing innovations can also be leveraged for the development and optimization of third-party vaccines through our platform.
AdJane’s proprietary nOMV platform serves as a versatile foundation for vaccine development: partners can apply the platform to their own antigens, supported by AdJane’s expertise in design, manufacturing and clinical translation.
The platform consolidates more than 30 years of Dutch public health vaccine research from RIVM, NVI, and Intravacc – institutes that have been international pioneers in vaccinology and have contributed extensively to the field, including the initiation of the Nm-nOMV platform research.
AdJane has transformed this fragmented but scientifically validated OMV technology base into an integrated platform. Through consolidation and expansion of IP, freedom-to-operate assessment, and significant investment in proprietary manufacturing and process innovations that bring the scientific foundation into operational practice, AdJane has created a platform designed for scalable development of a broad range of vaccine concepts.
